Results 61 to 70 of about 118,861 (266)

Protease inhibitors targeting coronavirus and filovirus entry. [PDF]

, 2015
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases.
Agudelo, Juliet, Barnard, Dale, Carrion, Ricardo, Lu, Kai, McKerrow, James H, Nunneley, Jerritt W, Pöhlmann, Stefan, Renslo, Adam R, Simmons, Graham, Vedantham, Punitha, Zhou, Yanchen   +10 more
core   +1 more source

A Nanoparticle‐Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes

Advanced Science, EarlyView.
We report a novel manufacture technology of chemically engineered exosomes. The four steps of manufacturing, i.e., biogenesis, loading, isolation, and storage, are integrated by the use of a nanoparticle. The manufacture technology incorporates three innovative components, i.e., a new nano‐bio effect, a new composite nanoparticle, and a new isolation ...
Xiaowei Wen, Zixing Xu, Zerun Hao, Yanming Chen, Kai Xie, Haofan Yin, Xueying Wang, Jie Min, Sihan Sun, Baiding Chen, Chengxiu Ling, Mingming Xu, Yizhao Chen, Gang Ruan   +13 more
wiley   +1 more source

Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative

Viruses
The HIV-1 aspartic protease is an effective target for the treatment of HIV/AIDS. Current therapy utilizes a selection of nine protease inhibitors (PIs) in combination with other classes of antiretroviral drugs.
Dean Sherry, Zaahida Sheik Ismail, Tshele Mokhantso, Yasien Sayed   +3 more
doaj   +1 more source

Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002

Annals of Clinical Microbiology and Antimicrobials, 2003
Background The prices of reverse transcriptase (RT) inhibitors in Thailand have been reduced since December 1, 2001. It is expected that reduction in the price of these inhibitors may influence the drug resistance mutation pattern of HIV-1 among infected
Watitpun Chotip, Jenwitheesuk Ekachai, Vibhagool Asda, Chantratita Wasun   +3 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

Retrovirology, 2011
Background Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles.
Konvalinka Jan, Maas Renée EM, Schipper Pauline J, Pokorná Jana, van Maarseveen Noortje M, Fun Axel, Nijhuis Monique   +6 more
doaj   +1 more source

Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses

Molecules, 2020
The inhibition of viral protease is an important target in antiviral drug discovery and development. To date, protease inhibitor drugs, especially HIV-1 protease inhibitors, have been available for human clinical use in the treatment of coronaviruses ...
Nakarin Suwannarach, Jaturong Kumla, Kanaporn Sujarit, Thanawat Pattananandecha, Chalermpong Saenjum, Saisamorn Lumyong   +5 more
doaj   +1 more source

Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor ntiretroviral regimens failed [PDF]

, 2004
The association between minor mutations in human immunodeficiency virus (HIV) protease at baseline and development of common primary mutation 90M at virological failure (conferring some resistance to all protease inhibitors [PIs]) was evaluated in 93
Antonella, D'Arminio Monforte, Balotta, Claudio, Bertoli, Ada, Cadeo, Giampiero, Chirianni, Antonio, Cozzi-Lepri, Alessandro, De Stefano, Carlo, Forbici, Federica, Mura, Maria Stella Anna, Orani, Anna, Perno, Carlo Federico, Violin, Michela   +11 more
core  

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources